Advanced ligand-based virtual screening to dramatically increase your wet screening hit rate at a fraction of the cost
We sought the scientific expertise within the Cresset Discovery Services team to utilize their novel field and shape-based virtual screening methods in Blaze™, and their proprietary Electrostatic Complementarity™ technique to help identify a backup series for our target effectively and efficiently. Ultimately we identified 9 novel chemotypes that were clearly distinct to those arising from docking and pharmacophore virtual screening approaches, which was an exciting outcome for us.
Dr Zara Sands, Head of CADD and Informatics, Confo Therapeutics, Belgium
Flare gives us an excellent assessment of the potential binding of hits. We use it to triage hits from Blaze and Forge experiments in the absence of 3D-QSAR, narrowing them down to an affordable subset of the most promising hits.
Dr Graeme Stevenson, Cancer Therapeutics CRC, Australia
This is a very important and exciting project for my team so thank you for your good work. The incredibly high hit rate from the Blaze compound list is intriguing.